Shareholders and the spineless board at Morrisons only have to look at the fortunes of Astrazeneca since 2014 to understand why rejecting financially driven overseas suitors is the right course. 
Astrazeneca (AZ) has soared up the FTSE 100 to become Britain’s…

Click here to view the original article.